{"title":"Il Significato di un titolo: Global e Regional Health Technology Assessment","authors":"C. Lucioni","doi":"10.33393/grhta.2014.311","DOIUrl":"https://doi.org/10.33393/grhta.2014.311","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117112345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The objective of this economic evaluation was to compare two alternative therapeutic regimens for the treatment of type 2 diabetes: basal-bolus insulin vs basal insulin and DPP-4. We conducted a Cost-Minimization Analysis (CMA) to compare the annual cost of basal-bolus insulin regimen vs basal insulin and DPP-4 regimen from the perspective of the Italian National Health Service (NHS). The CMA considered only direct medical costs (basal insulin, bolus insulin and DPP-4 [sitagliptin] and self-monitoring of glycemic control). Costs were assessed in 2014 Euros. Sensitivity analysis and threshold analysis on key economic parameters were performed. The expected annual cost (per patient) was €987.60 with basal insulin and DPP-4 and €1,568.23 with basal-bolus insulin. As a consequence of a significant reduction of glycemic control costs, the regimen with DPP-4 was a cost-saving alternative from the perspective of the Italian NHS.
{"title":"Economic Impact of Therapeutic Choices: The Case of Incretins","authors":"R. Ravasio","doi":"10.5301/GRHTA.5000181","DOIUrl":"https://doi.org/10.5301/GRHTA.5000181","url":null,"abstract":"The objective of this economic evaluation was to compare two alternative therapeutic regimens for the treatment of type 2 diabetes: basal-bolus insulin vs basal insulin and DPP-4. We conducted a Cost-Minimization Analysis (CMA) to compare the annual cost of basal-bolus insulin regimen vs basal insulin and DPP-4 regimen from the perspective of the Italian National Health Service (NHS). The CMA considered only direct medical costs (basal insulin, bolus insulin and DPP-4 [sitagliptin] and self-monitoring of glycemic control). Costs were assessed in 2014 Euros. Sensitivity analysis and threshold analysis on key economic parameters were performed. The expected annual cost (per patient) was €987.60 with basal insulin and DPP-4 and €1,568.23 with basal-bolus insulin. As a consequence of a significant reduction of glycemic control costs, the regimen with DPP-4 was a cost-saving alternative from the perspective of the Italian NHS.","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"295 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116224509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Equivalence, Similarity, Comparability, and Inter-Changeability of Pharmaceuticals: The Difficult way to Their Practical Application in Italy","authors":"M. de Rosa","doi":"10.33393/grhta.2014.314","DOIUrl":"https://doi.org/10.33393/grhta.2014.314","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116186150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-06-12DOI: 10.5301/GRHTA.2014.12359
Nicoletta Martone, C. Lucioni, S. Mazzi, V. Fadda
{"title":"New Oncological Drugs: Analysis of Survival Gain","authors":"Nicoletta Martone, C. Lucioni, S. Mazzi, V. Fadda","doi":"10.5301/GRHTA.2014.12359","DOIUrl":"https://doi.org/10.5301/GRHTA.2014.12359","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132313208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-06-12DOI: 10.5301/GRHTA.2014.12360
R. Gasparini, D. Amicizia, Piero Luigi Lai, C. Lucioni, D. Panatto
Vaccines are a basic investment in the long term, both for Countries and the whole world – where they are estimated to save 2.5 million lives among children each year. In this perspective vaccine r...
{"title":"Health Technology Assessment and vaccinations in Italy","authors":"R. Gasparini, D. Amicizia, Piero Luigi Lai, C. Lucioni, D. Panatto","doi":"10.5301/GRHTA.2014.12360","DOIUrl":"https://doi.org/10.5301/GRHTA.2014.12360","url":null,"abstract":"Vaccines are a basic investment in the long term, both for Countries and the whole world – where they are estimated to save 2.5 million lives among children each year. In this perspective vaccine r...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127755336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pitfalls in Clinical Research. The Case of the New Antineoplastic Agents","authors":"E. Ballatori, F. Roila, B. Ruggeri","doi":"10.5301/GRHTA.5000183","DOIUrl":"https://doi.org/10.5301/GRHTA.5000183","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125117052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In a previous publication, the incremental overall survival (OS gain vs current therapy) was estimated for the 32 new cancer therapies authorized in Italy between 2010 and 2013.The objective of this article was to quantify the respective incremental costs (including possible regulatory agreements) in order to build incremental cost-effectiveness ratios (ICERs) to be used for economic evaluation.In a first group of 12 therapies, where OS gains were statistically significant (p < 0.05), the ICERs' median value was €53,273 per year gained (range: 3,945 - 179,098) and the mean value was €64,181 (95% CI: 29,302 - 99,060). In the other group, excluding four therapies with negative OS gains, ICERs were calculated for the remaining 16 drugs. The median ICER resulted in €69,568 (range: 3,406 - 308,928) and the mean value was €87,330 (95% CI: 37,024 - 137,636).Assuming a threshold of €5,000 per life-month gained, a total of 14 new cancer therapies met this criterion of economic acceptability (eight out of 12 in the...
{"title":"Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy","authors":"Nicoletta Martone, C. Lucioni, S. Mazzi, V. Fadda","doi":"10.5301/GRHTA.5000182","DOIUrl":"https://doi.org/10.5301/GRHTA.5000182","url":null,"abstract":"In a previous publication, the incremental overall survival (OS gain vs current therapy) was estimated for the 32 new cancer therapies authorized in Italy between 2010 and 2013.The objective of this article was to quantify the respective incremental costs (including possible regulatory agreements) in order to build incremental cost-effectiveness ratios (ICERs) to be used for economic evaluation.In a first group of 12 therapies, where OS gains were statistically significant (p < 0.05), the ICERs' median value was €53,273 per year gained (range: 3,945 - 179,098) and the mean value was €64,181 (95% CI: 29,302 - 99,060). In the other group, excluding four therapies with negative OS gains, ICERs were calculated for the remaining 16 drugs. The median ICER resulted in €69,568 (range: 3,406 - 308,928) and the mean value was €87,330 (95% CI: 37,024 - 137,636).Assuming a threshold of €5,000 per life-month gained, a total of 14 new cancer therapies met this criterion of economic acceptability (eight out of 12 in the...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132282926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Codella, S. Coretti, A. Fiore, G. Rizzardini, M. Ruggeri
{"title":"Cost-Effectiveness Studies in HIV Treatment with Lopinavir/Ritonavir: A Review","authors":"P. Codella, S. Coretti, A. Fiore, G. Rizzardini, M. Ruggeri","doi":"10.5301/GRHTA.5000184","DOIUrl":"https://doi.org/10.5301/GRHTA.5000184","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131415873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：